Esben Laugesen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Esben Laugesen has a total of 286 co-authors. Here are the top co-authors by number of shared publications:
- Per Løgstrup Poulsen
Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark; Steno Diabetes Center, Aarhus University Hospital, 8200 Aarhus N, Denmark
27 shared publications - Kristian Løkke Funck
Steno Diabetes Center Aarhus, Aarhus University Hospital Aarhus Denmark
16 shared publications Per L. Poulsen
Clinical Medicine (S.G., P.L.P.), Aarhus University, Denmark
13 shared publications- Klavs Würgler Hansen
Medical Diagnostic Centre, Silkeborg Regional Hospital
12 shared publications - Liv Vernstrøm
Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark; Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark
12 shared publications - Søren Gullaksen
Dept. of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
10 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 40 (10)
Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial
- 29 August 2026
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 40 (10)
Open AccessEffects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial
- Open Access
- 25 July 2025
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 39 (10) , 109141
Effect of colchicine on platelet aggregation in patients with type 2 diabetes: Results from a randomized placebo-controlled trial
- 25 July 2025
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 39 (10) , 109141
Open AccessEffect of colchicine on platelet aggregation in patients with type 2 diabetes: Results from a randomized placebo-controlled trial
- Open Access
- 12 May 2025
- Published by Springer Nature in EJNMMI Research
- Vol. 15 (1) , 1-11
Test-retest repeatability of quantitative organ and tissue uptake using 20-minute dynamic multiparametric whole-body [18F]FDG PET/CT in patients with type 2 diabetes
Recently developed dynamic whole-body PET/CT (D-WB PET/CT) protocols allow for measurements of potentially more precise metabolic parameters than the commonly used semiquantitative SUV. Most notable is the metabolic rate of FDG uptake (MRFDG), which reflects quantitative glucose uptake into tissues and organs. However, data on the reproducibility of MRFDG measurements are scarce, particularly in patients with perturbed glucose homeostasis such as type 2 diabetes. We therefore aimed to evaluate the test-retest repeatability of both MRFDG and SUV in these patients. Fifteen participants (mean age 71 ± 7 years; 2 females) with type 2 diabetes underwent a short 20-minute [18F]FDG D-WB PET/CT after 6 h fasting on two consecutive days. Both SUV and MRFDG images were reconstructed from D-WB PET/CT data obtained 60–80 min post-injection of [18F]FDG. MRFDG and SUV data were measured in organs and tissues, and repeatability was assessed with Bland-Altman analysis, intraclass correlation coefficients (ICC), repeatability coefficients (RPC) and coefficients of variation (wCV). There was high repeatability of both SUVmean and MRFDG−mean in all measured organs (ICC range: 0.65–0.95 for SUVmean and 0.66–0.94 for MRFDG−mean). SUVmean generally demonstrated higher reliability (ICC) and lower variability (%RPC and %wCV) when compared to MRFDG−mean. However, MRFDG test-retest variation was < 19% in most analysed tissues, demonstrating that MRFDG may be used as a precise marker of treatment response. This study demonstrates that MRFDG calculated from D-WB PET/CT exhibit high repeatability, comparable to SUVs across most organs in patients with type 2 diabetes.
- 12 May 2025
- Published by Springer Nature in EJNMMI Research
- Vol. 15 (1) , 1-11
Open AccessTest-retest repeatability of quantitative organ and tissue uptake using 20-minute dynamic multiparametric whole-body [18F]FDG PET/CT in patients with type 2 diabetes
Recently developed dynamic whole-body PET/CT (D-WB PET/CT) protocols allow for measurements of potentially more precise metabolic parameters than the commonly used semiquantitative SUV. Most notable is the metabolic rate of FDG uptake (MRFDG), which reflects quantitative glucose uptake into tissues and organs. However, data on the reproducibility of MRFDG measurements are scarce, particularly in patients with perturbed glucose homeostasis such as type 2 diabetes. We therefore aimed to evaluate the test-retest repeatability of both MRFDG and SUV in these patients. Fifteen participants (mean age 71 ± 7 years; 2 females) with type 2 diabetes underwent a short 20-minute [18F]FDG D-WB PET/CT after 6 h fasting on two consecutive days. Both SUV and MRFDG images were reconstructed from D-WB PET/CT data obtained 60–80 min post-injection of [18F]FDG. MRFDG and SUV data were measured in organs and tissues, and repeatability was assessed with Bland-Altman analysis, intraclass correlation coefficients (ICC), repeatability coefficients (RPC) and coefficients of variation (wCV). There was high repeatability of both SUVmean and MRFDG−mean in all measured organs (ICC range: 0.65–0.95 for SUVmean and 0.66–0.94 for MRFDG−mean). SUVmean generally demonstrated higher reliability (ICC) and lower variability (%RPC and %wCV) when compared to MRFDG−mean. However, MRFDG test-retest variation was < 19% in most analysed tissues, demonstrating that MRFDG may be used as a precise marker of treatment response. This study demonstrates that MRFDG calculated from D-WB PET/CT exhibit high repeatability, comparable to SUVs across most organs in patients with type 2 diabetes.
- Open Access
- 10 April 2025
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 39 (6) , 109039
Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: A post-hoc analysis from a randomised trial
- 10 April 2025
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 39 (6) , 109039
Open AccessSemaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: A post-hoc analysis from a randomised trial
- 14 March 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (5) , 707-714
Colchicine mitigates arterial stiffness in high-risk patients with type 2 diabetes: a randomized placebo-controlled trial
Aims: The anti-inflammatory drug colchicine has been shown to reduce the risk of cardiovascular disease (CVD) in patients with and without diabetes. The underlying mechanisms are, however, elusive. In this trial, we investigated the effect of colchicine on arterial stiffness, ambulatory blood pressure, and albuminuria in patients with type 2 diabetes. Methods and results: We conducted a double-blind, randomized, placebo-controlled trial in individuals with type 2 diabetes with a history of CVD or a high risk thereof. One hundred participants were assigned in a 1:1 ratio to receive colchicine 0.5 mg once daily or placebo for 26 weeks. The primary outcome was change in arterial stiffness assessed as carotid-femoral pulse wave velocity (cfPWV). Secondary outcomes included 24-h ambulatory BP and urine albumin-to-creatinine ratio (UACR). Treatment with colchicine significantly mitigated arterial stiffness progression compared with placebo [mean arterial pressure (MAP)-adjusted change in cfPWV: −0.7 m/s, 95% CI: −1.3; −0.1, P = 0.03]. Crude analyses without MAP adjustment showed a non-significant reduction in cfPWV of −0.3 m/s (95% CI: −1.0; 0.4, P = 0.45). Colchicine had no significant effect on 24-h systolic ambulatory BP (change: 3.0 mmHg, 95% CI: −0.5; 6.5 mmHg, P = 0.10) or UACR (percentage change: 0.5, 95% CI: −29.5; 40.4, P = 0.98). Conclusion: This study suggests that low-dose colchicine may reduce arterial stiffness in high risk patients with type 2 diabetes. While these findings indicate that mitigating arterial stiffness contributes to the observed reduction in cardiovascular events in outcome trials, further research is needed to confirm these effects and understand the underlying mechanisms. Clinical trial registration information: EudraCT-no.: 2021-003525-30. Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003525-30/DK.
- 14 March 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (5) , 707-714
Colchicine mitigates arterial stiffness in high-risk patients with type 2 diabetes: a randomized placebo-controlled trial
Aims: The anti-inflammatory drug colchicine has been shown to reduce the risk of cardiovascular disease (CVD) in patients with and without diabetes. The underlying mechanisms are, however, elusive. In this trial, we investigated the effect of colchicine on arterial stiffness, ambulatory blood pressure, and albuminuria in patients with type 2 diabetes. Methods and results: We conducted a double-blind, randomized, placebo-controlled trial in individuals with type 2 diabetes with a history of CVD or a high risk thereof. One hundred participants were assigned in a 1:1 ratio to receive colchicine 0.5 mg once daily or placebo for 26 weeks. The primary outcome was change in arterial stiffness assessed as carotid-femoral pulse wave velocity (cfPWV). Secondary outcomes included 24-h ambulatory BP and urine albumin-to-creatinine ratio (UACR). Treatment with colchicine significantly mitigated arterial stiffness progression compared with placebo [mean arterial pressure (MAP)-adjusted change in cfPWV: −0.7 m/s, 95% CI: −1.3; −0.1, P = 0.03]. Crude analyses without MAP adjustment showed a non-significant reduction in cfPWV of −0.3 m/s (95% CI: −1.0; 0.4, P = 0.45). Colchicine had no significant effect on 24-h systolic ambulatory BP (change: 3.0 mmHg, 95% CI: −0.5; 6.5 mmHg, P = 0.10) or UACR (percentage change: 0.5, 95% CI: −29.5; 40.4, P = 0.98). Conclusion: This study suggests that low-dose colchicine may reduce arterial stiffness in high risk patients with type 2 diabetes. While these findings indicate that mitigating arterial stiffness contributes to the observed reduction in cardiovascular events in outcome trials, further research is needed to confirm these effects and understand the underlying mechanisms. Clinical trial registration information: EudraCT-no.: 2021-003525-30. Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003525-30/DK.
- 8 January 2025
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 27 (1) , 34-44
From Stability to Variability: Classification of Healthy Individuals, Prediabetes, and Type 2 Diabetes Using Glycemic Variability Indices from Continuous Glucose Monitoring Data
Objective: This study aims to investigate the continuum of glucose control from normoglycemia to dysglycemia (HbA1c ≥ 5.7%/39 mmol/mol) using metrics derived from continuous glucose monitoring (CGM). In addition, we aim to develop a machine learning-based classification model to classify dysglycemia based on observed patterns. Methods: Data from five distinct studies, each featuring at least two days of CGM, were pooled. Participants included individuals classified as healthy, with prediabetes, or with type 2 diabetes mellitus (T2DM). Various CGM indices were extracted and compared across groups. The data set was split 70/30 for training and testing two classification models (XGBoost/Logistic Regression) to differentiate between prediabetes or dysglycemia and the healthy group. Results: The analysis included 836 participants (healthy: n = 282; prediabetes: n = 133; T2DM: n = 432). Across all CGM indices, a progressive shift was observed from the healthy group to those with diabetes ( P < 0.001). Statistically significant differences ( P < 0.01) were noted in mean glucose, time below range, time above 140 mg/dl, mobility, multiscale complexity index, and glycemic risk index when transitioning from health to prediabetes. The XGBoost models achieved the highest receiver operating characteristic area under the curve values on the test data set ranging from 0.91 [confidence interval (CI): 0.87–0.95] (prediabetes identification) to 0.97 [CI: 0.95–0.98] (dysglycemia identification). Conclusion: Our findings demonstrate a gradual deterioration of glucose homeostasis and increased glycemic variability across the spectrum from normo- to dysglycemia, as evidenced by CGM metrics. The performance of CGM-based indices in classifying healthy individuals and those with prediabetes and diabetes is promising.
- 8 January 2025
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 27 (1) , 34-44
From Stability to Variability: Classification of Healthy Individuals, Prediabetes, and Type 2 Diabetes Using Glycemic Variability Indices from Continuous Glucose Monitoring Data
Objective: This study aims to investigate the continuum of glucose control from normoglycemia to dysglycemia (HbA1c ≥ 5.7%/39 mmol/mol) using metrics derived from continuous glucose monitoring (CGM). In addition, we aim to develop a machine learning-based classification model to classify dysglycemia based on observed patterns. Methods: Data from five distinct studies, each featuring at least two days of CGM, were pooled. Participants included individuals classified as healthy, with prediabetes, or with type 2 diabetes mellitus (T2DM). Various CGM indices were extracted and compared across groups. The data set was split 70/30 for training and testing two classification models (XGBoost/Logistic Regression) to differentiate between prediabetes or dysglycemia and the healthy group. Results: The analysis included 836 participants (healthy: n = 282; prediabetes: n = 133; T2DM: n = 432). Across all CGM indices, a progressive shift was observed from the healthy group to those with diabetes ( P < 0.001). Statistically significant differences ( P < 0.01) were noted in mean glucose, time below range, time above 140 mg/dl, mobility, multiscale complexity index, and glycemic risk index when transitioning from health to prediabetes. The XGBoost models achieved the highest receiver operating characteristic area under the curve values on the test data set ranging from 0.91 [confidence interval (CI): 0.87–0.95] (prediabetes identification) to 0.97 [CI: 0.95–0.98] (dysglycemia identification). Conclusion: Our findings demonstrate a gradual deterioration of glucose homeostasis and increased glycemic variability across the spectrum from normo- to dysglycemia, as evidenced by CGM metrics. The performance of CGM-based indices in classifying healthy individuals and those with prediabetes and diabetes is promising.
- Open Access
- 30 July 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (10) , 2175-2187
Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial
Aims/hypothesis: The apparent diffusion coefficient (ADC) derived from diffusion-weighted MRI (DWI-MRI) has been proposed as a measure of changes in kidney microstructure, including kidney fibrosis. In advanced kidney disease, the kidneys often become atrophic; however, in the initial phase of type 2 diabetes, there is an increase in renal size. Glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter 2 inhibitors both provide protection against progression of kidney disease in diabetes. However, the mechanisms are incompletely understood. To explore this, we examined the effects of semaglutide, empagliflozin and their combination on renal ADC and total kidney volume (TKV). Methods: This was a substudy of a randomised clinical trial on the effects of semaglutide and empagliflozin alone or in combination. Eighty patients with type 2 diabetes and high risk of CVD were randomised into four groups (n=20 in each) receiving either tablet placebo, empagliflozin, a combination of semaglutide and tablet placebo (herein referred to as the ‘semaglutide’ group), or the combination of semaglutide and empagliflozin (referred to as the ‘combination-therapy’ group). The semaglutide and the combination-therapy group had semaglutide treatment for 16 weeks and then had either tablet placebo or empagliflozin added to the treatment, respectively, for a further 16 weeks; the placebo and empagliflozin groups were treated with the respective monotherapy for 32 weeks. We analysed the effects of treatment on changes in ADC (cortical, medullary and the cortico–medullary difference [ΔADC; medullary ADC subtracted from cortical ADC]), as well as TKV measured by MRI. Results: Both semaglutide and empagliflozin decreased cortical ADC significantly compared with placebo (semaglutide: −0.20×10−3 mm2/s [95% CI −0.30, −0.10], p−3 mm2/s [95% CI −0.26, −0.04], p=0.01). No significant change was observed in the combination-therapy group (−0.05×10−3 mm2/s [95%CI −0.15, 0.05]; p=0.29 vs placebo). The changes in cortical ADC were not associated with changes in GFR, albuminuria, TKV or markers of inflammation. Further, there were no changes in medullary ADC in any of the groups compared with placebo. Only treatment with semaglutide changed ΔADC significantly from placebo, showing a decrease of −0.13×10−3 mm2/s (95% CI −0.22, −0.04; p=0.01). Compared with placebo, TKV decreased by −3% (95% CI −5%, −0.3%; p=0.04), −3% (95% CI −5%, −0.4%; p=0.02) and −5% (95% CI −8%, −2%; p1c. Conclusions/interpretation: In a population with type 2 diabetes and high risk of CVD, semaglutide and empagliflozin significantly reduced cortical ADC compared with placebo, indicating microstructural changes in the kidneys. These changes were not associated with changes in GFR, albuminuria or inflammation. Further, we found a decrease in TKV in all active treatment groups, which was possibly mediated by a reduction in hyperfiltration. Our findings suggest that DWI-MRI may serve as a promising tool for investigating the underlying mechanisms of medical interventions in individuals with type 2 diabetes but may reflect effects not related to fibrosis. Trial registration: European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) 2019-000781-38 Graphical
- 30 July 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (10) , 2175-2187
Open AccessEffects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial
Aims/hypothesis: The apparent diffusion coefficient (ADC) derived from diffusion-weighted MRI (DWI-MRI) has been proposed as a measure of changes in kidney microstructure, including kidney fibrosis. In advanced kidney disease, the kidneys often become atrophic; however, in the initial phase of type 2 diabetes, there is an increase in renal size. Glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter 2 inhibitors both provide protection against progression of kidney disease in diabetes. However, the mechanisms are incompletely understood. To explore this, we examined the effects of semaglutide, empagliflozin and their combination on renal ADC and total kidney volume (TKV). Methods: This was a substudy of a randomised clinical trial on the effects of semaglutide and empagliflozin alone or in combination. Eighty patients with type 2 diabetes and high risk of CVD were randomised into four groups (n=20 in each) receiving either tablet placebo, empagliflozin, a combination of semaglutide and tablet placebo (herein referred to as the ‘semaglutide’ group), or the combination of semaglutide and empagliflozin (referred to as the ‘combination-therapy’ group). The semaglutide and the combination-therapy group had semaglutide treatment for 16 weeks and then had either tablet placebo or empagliflozin added to the treatment, respectively, for a further 16 weeks; the placebo and empagliflozin groups were treated with the respective monotherapy for 32 weeks. We analysed the effects of treatment on changes in ADC (cortical, medullary and the cortico–medullary difference [ΔADC; medullary ADC subtracted from cortical ADC]), as well as TKV measured by MRI. Results: Both semaglutide and empagliflozin decreased cortical ADC significantly compared with placebo (semaglutide: −0.20×10−3 mm2/s [95% CI −0.30, −0.10], p−3 mm2/s [95% CI −0.26, −0.04], p=0.01). No significant change was observed in the combination-therapy group (−0.05×10−3 mm2/s [95%CI −0.15, 0.05]; p=0.29 vs placebo). The changes in cortical ADC were not associated with changes in GFR, albuminuria, TKV or markers of inflammation. Further, there were no changes in medullary ADC in any of the groups compared with placebo. Only treatment with semaglutide changed ΔADC significantly from placebo, showing a decrease of −0.13×10−3 mm2/s (95% CI −0.22, −0.04; p=0.01). Compared with placebo, TKV decreased by −3% (95% CI −5%, −0.3%; p=0.04), −3% (95% CI −5%, −0.4%; p=0.02) and −5% (95% CI −8%, −2%; p1c. Conclusions/interpretation: In a population with type 2 diabetes and high risk of CVD, semaglutide and empagliflozin significantly reduced cortical ADC compared with placebo, indicating microstructural changes in the kidneys. These changes were not associated with changes in GFR, albuminuria or inflammation. Further, we found a decrease in TKV in all active treatment groups, which was possibly mediated by a reduction in hyperfiltration. Our findings suggest that DWI-MRI may serve as a promising tool for investigating the underlying mechanisms of medical interventions in individuals with type 2 diabetes but may reflect effects not related to fibrosis. Trial registration: European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) 2019-000781-38 Graphical
- Open Access
- 13 May 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (7) , 1451
Correction: Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial
- 13 May 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (7) , 1451
Open AccessCorrection: Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial
- Top Cited PapersOpen Access
- 12 March 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (11) , 860-884
Metabolic Communication by SGLT2 Inhibition
BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect the kidneys and heart, but the underlying mechanism remains poorly understood. METHODS: To gain insights on primary effects of SGLT2i that are not confounded by pathophysiologic processes or are secondary to improvement by SGLT2i, we performed an in-depth proteomics, phosphoproteomics, and metabolomics analysis by integrating signatures from multiple metabolic organs and body fluids after 1 week of SGLT2i treatment of nondiabetic as well as diabetic mice with early and uncomplicated hyperglycemia. RESULTS: Kidneys of nondiabetic mice reacted most strongly to SGLT2i in terms of proteomic reconfiguration, including evidence for less early proximal tubule glucotoxicity and a broad downregulation of the apical uptake transport machinery (including sodium, glucose, urate, purine bases, and amino acids), supported by mouse and human SGLT2 interactome studies. SGLT2i affected heart and liver signaling, but more reactive organs included the white adipose tissue, showing more lipolysis, and, particularly, the gut microbiome, with a lower relative abundance of bacteria taxa capable of fermenting phenylalanine and tryptophan to cardiovascular uremic toxins, resulting in lower plasma levels of these compounds (including p-cresol sulfate). SGLT2i was detectable in murine stool samples and its addition to human stool microbiota fermentation recapitulated some murine microbiome findings, suggesting direct inhibition of fermentation of aromatic amino acids and tryptophan. In mice lacking SGLT2 and in patients with decompensated heart failure or diabetes, the SGLT2i likewise reduced circulating p-cresol sulfate, and p-cresol impaired contractility and rhythm in human induced pluripotent stem cell–derived engineered heart tissue. CONCLUSIONS: SGLT2i reduced microbiome formation of uremic toxins such as p-cresol sulfate and thereby their body exposure and need for renal detoxification, which, combined with direct kidney effects of SGLT2i, including less proximal tubule glucotoxicity and a broad downregulation of apical transporters (including sodium, amino acid, and urate uptake), provides a metabolic foundation for kidney and cardiovascular protection.
- 12 March 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (11) , 860-884
Top Cited PapersOpen AccessMetabolic Communication by SGLT2 Inhibition
BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect the kidneys and heart, but the underlying mechanism remains poorly understood. METHODS: To gain insights on primary effects of SGLT2i that are not confounded by pathophysiologic processes or are secondary to improvement by SGLT2i, we performed an in-depth proteomics, phosphoproteomics, and metabolomics analysis by integrating signatures from multiple metabolic organs and body fluids after 1 week of SGLT2i treatment of nondiabetic as well as diabetic mice with early and uncomplicated hyperglycemia. RESULTS: Kidneys of nondiabetic mice reacted most strongly to SGLT2i in terms of proteomic reconfiguration, including evidence for less early proximal tubule glucotoxicity and a broad downregulation of the apical uptake transport machinery (including sodium, glucose, urate, purine bases, and amino acids), supported by mouse and human SGLT2 interactome studies. SGLT2i affected heart and liver signaling, but more reactive organs included the white adipose tissue, showing more lipolysis, and, particularly, the gut microbiome, with a lower relative abundance of bacteria taxa capable of fermenting phenylalanine and tryptophan to cardiovascular uremic toxins, resulting in lower plasma levels of these compounds (including p-cresol sulfate). SGLT2i was detectable in murine stool samples and its addition to human stool microbiota fermentation recapitulated some murine microbiome findings, suggesting direct inhibition of fermentation of aromatic amino acids and tryptophan. In mice lacking SGLT2 and in patients with decompensated heart failure or diabetes, the SGLT2i likewise reduced circulating p-cresol sulfate, and p-cresol impaired contractility and rhythm in human induced pluripotent stem cell–derived engineered heart tissue. CONCLUSIONS: SGLT2i reduced microbiome formation of uremic toxins such as p-cresol sulfate and thereby their body exposure and need for renal detoxification, which, combined with direct kidney effects of SGLT2i, including less proximal tubule glucotoxicity and a broad downregulation of apical transporters (including sodium, amino acid, and urate uptake), provides a metabolic foundation for kidney and cardiovascular protection.
- 15 January 2024
- Published by Wolters Kluwer Health in Blood Pressure Monitoring
- Vol. 29 (2) , 82-88
Feasibility of Arteriograph 24 for evaluation of 24-hour pulse wave velocity and central blood pressure in patients with type 2 diabetes and non-diabetic controls
The objective of this study was to assess the feasibility of the Arteriograph 24 device to measure 24-hour PWV and central systolic blood pressure (cSBP) in patients with type 2 diabetes (T2DM) and non-diabetic controls and compare daytime and nighttime characteristics in the two groups. Twenty-four-hour PWV and cSBP was measured in 58 patients with T2DM (mean age: 66 ± 9 years, 50% women, mean duration of T2DM: 7.8 ± 1.5 years) and 62 age- and sex-matched controls. Seventy percent of participants (71% T2DM patients and 69% controls) had sufficient readings to generate an acceptable 24-hour report (≥14 day and ≥7 night readings). Lower nocturnal than daytime PWV and cSBP were observed in both groups. Nocturnal PWV and cSBP dipping were attenuated in T2DM patients compared to controls (PWV: −0.3 ± 0.9 vs. −0.7 ± 0.9 m/s, P = 0.04, cSBP: −8 ± 14 vs. −18 ± 18 mmHg, P < 0.01). No group differences in PWV or cSBP were observed during daytime (T2D vs. controls, PWV: 9.2 ± 1.1 vs. 9.2 ± 1.3 m/s, P = 0.99, cSBP: 133 ± 19 vs. 137 ± 25 mmHg, P = 0.42) or nighttime (PWV: 8.9 ± 1.3 vs. 8.4 ± 1.3 m/s, P = 0.14, cSBP 124 ± 20 vs. 118 ± 27 mmHg, P = 0.26). The study findings indicate that the nocturnal dipping of PWV and cSBP is attenuated in T2DM patients. The significant number of missing measurements raises concerns regarding the clinical utility of the Arteriograph 24 device.
- 15 January 2024
- Published by Wolters Kluwer Health in Blood Pressure Monitoring
- Vol. 29 (2) , 82-88
Feasibility of Arteriograph 24 for evaluation of 24-hour pulse wave velocity and central blood pressure in patients with type 2 diabetes and non-diabetic controls
The objective of this study was to assess the feasibility of the Arteriograph 24 device to measure 24-hour PWV and central systolic blood pressure (cSBP) in patients with type 2 diabetes (T2DM) and non-diabetic controls and compare daytime and nighttime characteristics in the two groups. Twenty-four-hour PWV and cSBP was measured in 58 patients with T2DM (mean age: 66 ± 9 years, 50% women, mean duration of T2DM: 7.8 ± 1.5 years) and 62 age- and sex-matched controls. Seventy percent of participants (71% T2DM patients and 69% controls) had sufficient readings to generate an acceptable 24-hour report (≥14 day and ≥7 night readings). Lower nocturnal than daytime PWV and cSBP were observed in both groups. Nocturnal PWV and cSBP dipping were attenuated in T2DM patients compared to controls (PWV: −0.3 ± 0.9 vs. −0.7 ± 0.9 m/s, P = 0.04, cSBP: −8 ± 14 vs. −18 ± 18 mmHg, P < 0.01). No group differences in PWV or cSBP were observed during daytime (T2D vs. controls, PWV: 9.2 ± 1.1 vs. 9.2 ± 1.3 m/s, P = 0.99, cSBP: 133 ± 19 vs. 137 ± 25 mmHg, P = 0.42) or nighttime (PWV: 8.9 ± 1.3 vs. 8.4 ± 1.3 m/s, P = 0.14, cSBP 124 ± 20 vs. 118 ± 27 mmHg, P = 0.26). The study findings indicate that the nocturnal dipping of PWV and cSBP is attenuated in T2DM patients. The significant number of missing measurements raises concerns regarding the clinical utility of the Arteriograph 24 device.